Project information

Chemotherapy resistance in ovarian cancer

To find a new, more effective treatment for ovarian cancer to improve women's chances of survival.

February 2011 - February 2014

Charity information: Wellbeing of Women

Wellbeing of Women logo
  • Need

    Need

    59% of women with ovarian cancer will die within 5 years of diagnosis. The survival rates are so low, because many women develop a resistance to conventional chemotherapy.

    Solution

    Predicting which women will develop a resistance to chemotherapy, will mean that alternative treatments can be given.

    This project will investigate the role of a particular protein (LARP1), that has the ability to make cancer cells 'turn nasty'.

  • Aims

    Aim 1

    To predict which women with ovarian cancer will develop a resistance to chemotherapy.

    Activities

    » It will investigate the role of a particular protein (LARP1), that has the ability to make cancer cells 'turn nasty'.

    The research team hope to develop simple blood test which has the potential to show which women will be resistant to conventional chemotherapy.


  • Impact

    Impact

    The project will have an important impact on our understanding of what causes resistance in ovarian cancer.

    If patients who will develop a resistance to chemotherapy are identified, these women can avoid unnecessary gruelling and toxic treatment.

    Risk

    We mitigate risk by ensuring that only the best medical research is selected via our Research Advisory Committee and peer review process.

    Reporting

    Our biannual Research Newsletter can be sent out to donors. It updates our supporters on our current research projects and training scholarships

  • Budget

    Budget - Project Cost: £183,855

    Loading graph....
      Amount Heading Description
      £40,580 Consumable (Over 3 years)
      £143,275 Salaries (Over 3 years)
  • Background

    Location

    The project will take place at Imperial College London.

    Beneficiaries

    Women needing treatment from ovarian cancer will benefit from this project.

  • Why Us?

    Why Us?

    For 50 years we have been funding pioneering medical research that has resulted in some remarkable progress. The work we fund with continue to develop better treatments.

    Read more about the Charity running this project.

    People

    Dr Sarah Blagden

    Dr Blagden is the lead investigator on this project. She will be supported by two others.

I have repeatedly witnessed the terrible destruction that cancer causes. It makes me angry, and motivates me to do my bit to find a cure

Dr Sarah Blagden